For immediate release |
25 March 2011 |
Futura Medical plc
("Futura" or "the Company")
Director's Share Dealing
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that Derek Martin, Finance Director, has today exercised options over 100,000 new ordinary shares of 0.2p each in the Company at a price of £0.43 per share.
The new ordinary shares resulting from the exercise of options will rank pari passu with existing ordinary shares and are expected to be admitted to trading on AIM at 8.00am on 31 March 2011.
Following the transactions, Mr Martin's beneficial and non-beneficial holding in ordinary shares in the Company for the purposes of the AIM Rules for Companies will be 225,000 ordinary shares, representing 0.31% of the Company's share capital.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive
|
Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com |
|
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny |
Tel:+44 (0)20 7776 1200 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan Communications |
|
Mark Court / Jessica Fontaine |
Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.